Search clinical trials for: HLA-A*02:01-restricted VEGFR1-derived peptide vaccination

Total 6 results

Tokyo University
Human Genome Center, Institute of Medical Science, University of Tokyo

Terminated

Human Leukocyte Antigen-A*02:01-restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer

Pancreatic Cancer | Pancreas Neoplasms

Japan
Shiga University
Tokyo University

Completed

Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*24 or A*02-positive Advanced Solid Tumors

Solid Tumors

Japan
Shiga University
Human Genome Center, Institute of Medical Science, University of Tokyo

Completed

Safety Study of Peptide Cancer Vaccine To Treat HLA-A*02-positive Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

Japan
Shiga University
Human Genome Center, Institute of Medical Science, University of Tokyo

Completed

Safety Study of Peptide Cancer Vaccine To Treat HLA-A*24-positive Advanced Small Cell Lung Cancer

Small Cell Lung Cancer

Japan
ImmunoVaccine Technologies, Inc. (IMV Inc.)

Completed

A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer

Breast Neoplasms | Prostatic Neoplasms | Ovarian Neoplasms

United States
National Cancer Institute (NCI)

Terminated

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive

Melanoma | Cervical Cancer | Breast Cancer | Bladder Cancer | Renal Cancer

United States

3

Subscribe